Century Therapeutics Reports Promising Preclinical Data for Type 1 Diabetes

Key Facts

Amid the global race to develop functional cures for chronic diseases, Century Therapeutics has unveiled promising preclinical data for its Type 1 diabetes candidate, CNTY-813. According to reports, the iPSC-derived islet replacement therapy demonstrated durable glucose control for over eight months in diabetic mice. The therapy utilizes the company's proprietary Allo-Evasion 5.0 technology, designed to allow transplanted cells to evade immune rejection, potentially eliminating the long-term requirement for immunosuppressive drugs.

This breakthrough places Century in direct competition with biotech giants like Vertex Pharmaceuticals and Eli Lilly, who are also pioneering cell therapies for diabetes. While Vertex has already moved into advanced clinical stages per market data, Century’s results are notable for showing no signs of tumorigenesis, a critical safety hurdle for stem-cell-derived treatments. This success in animal models provides a foundational proof-of-concept for the company’s immune-evasion platform compared to existing industry benchmarks.

Looking ahead, the company aims to submit an Investigational New Drug (IND) application in Q4 2026, with clinical data not expected until at least 2027. Investors should monitor broader market sentiment following the recent US Unemployment Rate release (4.3% as of June 5, 2026), which dictates the funding environment for pre-revenue biotech firms. Key catalysts include further safety validation studies and updates on the regulatory filing timeline toward the end of next year.